APA (7th ed.) Citation

Bacher, U., Kern, W., Alpermann, T., Schnittger, S., Kohlmann, A., Klein, H., . . . Haferlach, T. (2011). Prognosis in patients with MDS or AML and bone marrow blasts between 10% and 30% is not associated with blast counts but depends on cytogenetic and molecular genetic characteristics. Leukemia (08876924), 25(8), 1361. https://doi.org/10.1038/leu.2011.80

Chicago Style (17th ed.) Citation

Bacher, U., W. Kern, T. Alpermann, S. Schnittger, A. Kohlmann, H.-U Klein, M. Dugas, C. Haferlach, and T. Haferlach. "Prognosis in Patients with MDS or AML and Bone Marrow Blasts Between 10% and 30% Is Not Associated with Blast Counts but Depends on Cytogenetic and Molecular Genetic Characteristics." Leukemia (08876924) 25, no. 8 (2011): 1361. https://doi.org/10.1038/leu.2011.80.

MLA (9th ed.) Citation

Bacher, U., et al. "Prognosis in Patients with MDS or AML and Bone Marrow Blasts Between 10% and 30% Is Not Associated with Blast Counts but Depends on Cytogenetic and Molecular Genetic Characteristics." Leukemia (08876924), vol. 25, no. 8, 2011, p. 1361, https://doi.org/10.1038/leu.2011.80.